By Dean SealShares of CureVac fell to an all-time low after the company said a German federal court has denied the validity of an intellectual property patent related to messenger ribonucleic acid technology in Covid-19 vaccines. The stock dropped 41% to a low of $3.41 on Tuesday. The German biopharmaceutical company said the German Federal Patent Court granted a nullity action filed against CureVac's patent by rival BioNTech. The two competitors are in ongoing patent litigation involving eight CureVac intellectual property rights. CureVac said it will appeal the German court's decision.

Source: Wall Street Journal December 20, 2023 00:49 UTC